Volume 139, Issue 4, Pages (October 2010)

Slides:

Advertisements

Similar presentations

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis.

Advertisements

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Copyright © 2012 American Medical Association. All rights reserved.

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Volume 149, Issue 6, Pages (November 2015)

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.

Volume 146, Issue 2, Pages e6 (February 2014)

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

Volume 139, Issue 4, Pages (October 2010)

Volume 139, Issue 5, Pages e1 (November 2010)

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals Susanna Naggie, Mark S. Sulkowski Gastroenterology

Volume 44, Issue 4, Pages (April 2006)

Volume 146, Issue 5, Pages (May 2014)

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

Volume 153, Issue 4, Pages (October 2017)

Volume 146, Issue 3, Pages e1 (March 2014)

Volume 143, Issue 3, Pages e5 (September 2012)

Peginterferon alfa-2b plus ribavirin for chronic hepatitis

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

Volume 149, Issue 4, Pages e1 (October 2015)

Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection Steven L. Flamm, Eric Lawitz,

Volume 154, Issue 8, Pages e8 (June 2018)

Volume 146, Issue 2, Pages (February 2014)

A Historical Perspective on Clinical Advances in Pancreatic Diseases

Volume 154, Issue 4, Pages (March 2018)

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse

Volume 155, Issue 5, Pages e2 (November 2018)

Jean-Michel Pawlotsky Gastroenterology

Volume 141, Issue 5, Pages (November 2011)

Volume 146, Issue 2, Pages e6 (February 2014)

Volume 146, Issue 7, Pages e3 (June 2014)

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV.

Volume 151, Issue 6, Pages (December 2016)

Volume 136, Issue 2, Pages (February 2009)

Acute hepatitis C: Current status and remaining challenges

Volume 130, Issue 4, Pages (April 2006)

Volume 145, Issue 5, Pages e5 (November 2013)

Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients Vincent G. Bain, Kelly D.

Volume 142, Issue 6, Pages (May 2012)

Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C David R. Nelson, Vinod Rustgi, Vijayan.

Volume 139, Issue 4, Pages e4 (October 2010)

Volume 138, Issue 7, Pages (June 2010)

Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review Gennaro D’Amico, Juan Carlos Garcia-Pagan,

Volume 138, Issue 1, Pages e2 (January 2010)

Rafael Esteban, Maria Buti Gastroenterology

Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis.

Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection Elliot.

Volume 140, Issue 7, Pages (June 2011)

Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease Markus.

Volume 145, Issue 4, Pages e3 (October 2013)

Volume 136, Issue 7, Pages e4 (June 2009)

Volume 123, Issue 4, Pages (October 2002)

Volume 139, Issue 6, Pages (December 2010)

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection Yoav Lurie, Regine Rouzier-Panis, George.

Volume 143, Issue 3, Pages e5 (September 2012)

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Hepatitis C treatment in patients with kidney disease

Covering the Cover Gastroenterology

Yun-Fan Liaw, Wen-Juei Jeng, Ming-Ling Chang Gastroenterology

Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels Mitchell L. Shiffman, Moisés Diago, Albert Tran, Paul Pockros, Robert.

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Clinical Gastroenterology and Hepatology

Volume 139, Issue 5, Pages (November 2010)

Volume 137, Issue 6, Pages (December 2009)

Volume 147, Issue 6, Pages (December 2014)

Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami,

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,

Presentation transcript:

Volume 139, Issue 4, Pages 1257-1266 (October 2010) Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1 Stefan Zeuzem, Mark S. Sulkowski, Eric J. Lawitz, Vinod K. Rustgi, Maribel Rodriguez–Torres, Bruce R. Bacon, Mircea Grigorescu, Alan D. Tice, Yoav Lurie, Janusz Cianciara, Andrew J. Muir, Patrick W. Cronin, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison Gastroenterology Volume 139, Issue 4, Pages 1257-1266 (October 2010) DOI: 10.1053/j.gastro.2010.06.066 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Summary of patient disposition and completion of treatment. albIFN, albinterferon alfa-2b; EVR12, early virologic response at week 12; HCV, hepatitis C virus; Peg-IFNα-2a, pegylated interferon-α-2a. Gastroenterology 2010 139, 1257-1266DOI: (10.1053/j.gastro.2010.06.066) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Intention-to-treat analysis of virologic response. (A) Rates of sustained virologic response (SVR), defined as hepatitis C virus (HCV) RNA <15 IU/mL at week 72. (B) Rates of HCV RNA <15 IU/mL during treatment (weeks 4, 12, 24, and 48) and rates of relapse (proportion of patients with HCV RNA < 15 IU/mL at week 48 who failed to achieve SVR). albIFN, albinterferon alfa-2b; Peg-IFNα-2a, pegylated interferon-α-2a. Gastroenterology 2010 139, 1257-1266DOI: (10.1053/j.gastro.2010.06.066) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Predictors of sustained virologic response by multivariate regression model. Multivariate logistic regression model–based adjusted odds ratios and associated 95% confidence intervals (CIs) for factors provided along the y-axis. Plotting symbol represents odds ratio and horizontal line spans coverage of CI. Vertical reference line at 1 indicates no difference. albIFN, albinterferon alfa-2b; ALT, alanine aminotransferase; F, fibrosis score; GGT, γ-glutamyl transpeptidase; HCV, hepatitis C virus; Peg-IFNα-2a, pegylated interferon-α-2a; ULN, upper limit of normal. Gastroenterology 2010 139, 1257-1266DOI: (10.1053/j.gastro.2010.06.066) Copyright © 2010 AGA Institute Terms and Conditions